MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta
⏸️ MapLight Therapeutics pauses preclinical and discovery work: The biotech said it will instead focus its resources on advancing its lead candidate, ML-007C-MA, for schizophrenia and Alzheimer’s disease psychosis. MapLight also ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.